TapewireFind a company

person · Reporting owner

Fitzgerald Kevin Joseph

Disclosed activity across 2 companies

Tapewire entity
53095
SEC CIK
0001886431

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132CSO & EVP, Head of ResearchMarch 04, 2026March 06, 2026
Ovid Therapeutics Inc.OVID · Entity 5411DirectorApril 07, 2026April 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date March 04, 2026 · Filed March 06, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect20,569 Ending reported balance After 2026-03-05 transaction · row 12
12 source rows · reconciled sequence

Row 1 · 2026-03-04 · Sale · Disposed 29 · Balance 21,831

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 2 · 2026-03-04 · Sale · Disposed 28 · Balance 21,803

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 3 · 2026-03-04 · Sale · Disposed 59 · Balance 21,744

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 4 · 2026-03-04 · Sale · Disposed 79 · Balance 21,665

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 5 · 2026-03-04 · Sale · Disposed 96 · Balance 21,569

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 6 · 2026-03-04 · Sale · Disposed 210 · Balance 21,359

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 7 · 2026-03-04 · Sale · Disposed 75 · Balance 21,284

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 8 · 2026-03-04 · Sale · Disposed 57 · Balance 21,227

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 9 · 2026-03-05 · Sale · Disposed 124 · Balance 21,103

F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.

F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 10 · 2026-03-05 · Sale · Disposed 233 · Balance 20,870

F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.

F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 11 · 2026-03-05 · Sale · Disposed 148 · Balance 20,722

F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.

F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 12 · 2026-03-05 · Sale · Disposed 153 · Balance 20,569

F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.

F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Common StockSEC Table I · non-derivativeIndirectby Managed Account537 Reported balance Holding disclosure · report date 2026-03-04 · row 13 Holding and transaction disclosures are not merged.
1 source row

Row 13 · Balance 537

F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.

F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

Ovid Therapeutics Inc.

Report date April 07, 2026 · Filed April 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect17,578 Reported balance After 2026-04-07 transaction · row 1
1 source row

Row 1 · 2026-04-07 · Grant · Acquired 17,578 · Balance 17,578

F1: Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 04, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 324 $241.68 $78,304.32
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 14

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,572

F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.40 to $241.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 04, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 328 $240.95 $79,031.60
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 13

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,896

F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.18 to $241.17. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 04, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 121 $239.24 $28,948.04
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 12

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,224

F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.93 to $239.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 7,819 $0.00 Strike: $243.53 $0.00
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · derivative · entry 17

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,819

Underlying: Common Stock · 7,819 shares

Expires 2035-03-03

F17 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 219 $245.30 $53,720.70
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 11

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,345

F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.80 to $245.74. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 487 $243.94 $118,798.78
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 10

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,564

F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.37 to $244.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 465 $242.69 $112,850.85
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 9

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,051

F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.20 to $242.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 1 $248.36 $248.36
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 8

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,516

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 4 $247.35 $989.40
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 7

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,517

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.04 to $247.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 45 $246.18 $11,078.10
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 6

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,521

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $246.00 to $246.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 111 $245.26 $27,223.86
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 5

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,566

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.91 to $245.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 151 $244.41 $36,905.91
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 4

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,677

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 224 $243.36 $54,512.64
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 3

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,828

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.89 to $243.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 204 $242.37 $49,443.48
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 2

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,052

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.87 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:22 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 3,871 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 1

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,256

F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:30 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 37 $244.11 $9,032.07
Disclosure

SEC source: 0001735276-25-000019 · edgardoc.xml · nonDerivative · entry 8

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,385

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on February 27, 2023.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.32. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:30 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 75 $243.23 $18,242.25
Disclosure

SEC source: 0001735276-25-000019 · edgardoc.xml · nonDerivative · entry 7

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,422

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on February 27, 2023.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.87 to $243.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:30 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 187 $242.44 $45,336.28
Disclosure

SEC source: 0001735276-25-000019 · edgardoc.xml · nonDerivative · entry 6

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,497

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on February 27, 2023.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.86 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:30 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 79 $241.51 $19,079.29
Disclosure

SEC source: 0001735276-25-000019 · edgardoc.xml · nonDerivative · entry 5

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,684

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on February 27, 2023.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.85 to $241.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:30 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 48 $240.32 $11,535.36
Disclosure

SEC source: 0001735276-25-000019 · edgardoc.xml · nonDerivative · entry 4

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,763

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on February 27, 2023.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $239.82 to $240.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:30 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 22 $239.18 $5,261.96
Disclosure

SEC source: 0001735276-25-000019 · edgardoc.xml · nonDerivative · entry 3

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,811

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on February 27, 2023.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.73 to $239.69. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:30 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 21 $238.33 $5,004.93
Disclosure

SEC source: 0001735276-25-000019 · edgardoc.xml · nonDerivative · entry 2

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,833

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on February 27, 2023.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $237.72 to $238.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2025 Filed Mar 3, 2025 21:30 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 27 $236.51 $6,385.77
Disclosure

SEC source: 0001735276-25-000019 · edgardoc.xml · nonDerivative · entry 1

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,854

F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on February 27, 2023.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $236.50 to $237.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 20, 2025 Filed Jun 18, 2025 20:45 UTC Ovid Therapeutics Inc. OVID · Entity 5411 GrantStock Option (right to buy) · Derivative 45,000 $0.00 Strike: $0.57 $0.00
Disclosure

SEC source: 0001415889-25-017698 · form4-06182025_040608.xml · derivative · entry 1

Fitzgerald Kevin Joseph · CIK 0001886431 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2035-02-19

F1 · derivative.exercise_date: The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date.

Read SEC document
February 18, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 83 $259.10 $21,505.30
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 18

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,881

F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

Read SEC document
February 18, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 76 $257.79 $19,592.04
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 17

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,964

F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

Read SEC document
February 18, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 80 $256.05 $20,484.00
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 16

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,040

F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F15 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $256.00 to $256.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 18, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 115 $251.60 $28,934.00
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 15

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,120

F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

Read SEC document
February 18, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 1,086 $250.21 $271,728.06
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 14

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,235

F13 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.81 to $250.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 14 $264.87 $3,708.18
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 13

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,321

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 12 $263.33 $3,159.96
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 12

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,335

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 26 $261.45 $6,797.70
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 11

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,347

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $261.42 to $261.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 21 $260.57 $5,471.97
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 10

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,373

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $260.31 to $260.96. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 12 $259.72 $3,116.64
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 9

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,394

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $259.21 to $260.14. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 33 $258.07 $8,516.31
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 8

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,406

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.86 to $258.44. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 26 $257.51 $6,695.26
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 7

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,439

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $257.05 to $257.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 53 $256.29 $13,583.37
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 6

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,465

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $256.01 to $256.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 47 $255.56 $12,011.32
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 5

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,518

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $254.99 to $255.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 110 $254.35 $27,978.50
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 4

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,565

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $253.96 to $254.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 164 $253.37 $41,552.68
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 3

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,675

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.90 to $253.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 145 $252.50 $36,612.50
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 2

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,839

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.89 to $252.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:47 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 2,103 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000010 · edgardoc.xml · nonDerivative · entry 1

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,984

F1 · kind: On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting achievement, on or before December 31, 2025, of non-GAAP operating income profitability for a 12-month calendar year, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 13, 2025.

Read SEC document
December 12, 2024 Filed Dec 16, 2024 21:15 UTC Ovid Therapeutics Inc. OVID · Entity 5411 GrantStock Option (Right to Buy) · Derivative 90,000 $0.00 Strike: $1.06 $0.00
Disclosure

SEC source: 0001415889-24-029474 · form4-12162024_041217.xml · derivative · entry 1

Fitzgerald Kevin Joseph · CIK 0001886431 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2034-12-11

F1 · derivative.exercise_date: The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date.

Read SEC document
November 27, 2024 Filed Nov 27, 2024 22:20 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 110 $254.48 $27,992.80
Disclosure

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 10

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,881

F8 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

Read SEC document
November 27, 2024 Filed Nov 27, 2024 22:20 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 360 $253.44 $91,238.40
Disclosure

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 9

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,991

F8 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $253.07 to $254.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 27, 2024 Filed Nov 27, 2024 22:20 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 851 $251.98 $214,434.98
Disclosure

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 8

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,351

F8 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.76 to $252.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 27, 2024 Filed Nov 27, 2024 22:20 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 210 $250.45 $52,594.50
Disclosure

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 7

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,202

F8 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.27 to $250.62. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 26, 2024 Filed Nov 27, 2024 22:20 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 84 $252.27 $21,190.68
Disclosure

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 6

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,412

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $252.09 to $252.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 26, 2024 Filed Nov 27, 2024 22:20 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 826 $251.42 $207,672.92
Disclosure

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 5

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,496

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.07 to $252.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 26, 2024 Filed Nov 27, 2024 22:20 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 318 $250.68 $79,716.24
Disclosure

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 4

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,322

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.05 to $251.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.